Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor suppressor protein
p53
(
p53
) is a master transcription factor that plays key roles in cell cycle arrest, apoptosis, senescence, and metabolism, as well as regulation of innate immunity during virus infection. In order to facilitate their replication and spreading, viruses have evolved to manipulate
p53
function through different strategies, with some requiring active
p53
while others demand reduction/inhibition of
p53
activity. However, there are no clear-cut reports about the roles of
p53
during the infection of foot-and-mouth disease virus (FMDV), the causative agent of a highly contagious foot-and-mouth disease (FMD) of cloven-hoofed animals. Here we showed that
p53
level was dynamically regulated during FMDV infection, being degraded at the early infection stage but recovered to the basal level at the late stage. Cells depleted of
p53
showed inhibited FMDV replication and enhanced expression of the immune-related genes, whereas overexpression of
p53
didn't affect the viral replication. Viral challenge assay with
p53
knockout mice obtained similar results, with viral load decreased, histopathological changes alleviated, and lifespan extended in the
p53
knockout mice. Together, these data demonstrate that basal level
p53
is required for efficient FMDV replication by suppressing the innate immunity.
...
PMID:Basal Level p53 Suppresses Antiviral Immunity against Foot-and-Mouth Disease Virus. 3139 68
Breast cancer patients treated with adjuvant chemotherapy regimens containing alkylating agents and anthracyclines are at an increased risk for secondary myeloid malignancies, either acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Complex genomic changes (karyotypes and/or gene amplification) accompany the development of the secondary neoplasms. Here we present a unique case of a breast cancer patient who developed secondary AML within 18 months of treatment with trastuzumab, pertuzumab, docetaxel, carboplatin (
TCHP
) and radiation. Leukemia cells had catastrophic alterations in chromosomes 8, 11, and 17. Genetic abnormalities in the leukemia cells included amplification of MYC and KMT2A as double minutes, and deletion and mutational inactivation of
TP53
Concurrent amplification of different genes at different levels and on different double minutes, we have named "double minute heterogeneity." Clinically, this case highlights the need to identify genes amplified in secondary myeloid malignancies by cytogenomic microarray (CMA) analysis since these may have therapeutic implications.
...
PMID:Cytogenomic characterization of double minute heterogeneity in therapy related acute myeloid leukemia. 3142 28
Tumor suppressor protein
p53
, which functions in the cell cycle, apoptosis and neuronal differentiation via transcriptional regulations of target genes or interactions with several proteins, has been associated with neurite outgrowth through microtubule re-organization. We previously demonstrated in neurons that upon
p53
induction, the level of microtubule severing protein Katanin-p60 increases, indicating that
p53
might be a transcriptional regulator of the KATNA1 gene encoding Katanin-p60. In this context, we firstly elucidated the activity of KATNA1 regulatory regions and endogenous KATNA1 mRNA levels in the presence or absence of
p53
using HCT 116 WT and HCT 116
p53
(-/-) cells. Next, we demonstrated the binding of
p53
to the KATNA1 promoter and then investigated the role of
p53
on KATNA1 gene expression by ascertaining KATNA1 mRNA and Katanin-p60 protein levels upon
p53
overexpression and activation in both cells. Moreover, we showed changes in microtubule network upon increased Katanin-p60 level due to
p53
overexpression. Also, the changes in KATNA1 mRNA and Katanin-p60 protein levels upon
p53
knockdown were investigated. Our results indicate that
p53
is an activator of KATNA1 gene expression and we show that both
p53
and Katanin-p60 expression have strict regulations and are maintained at balanced levels as they are vital proteins to orchestrate either survival and apoptosis or differentiation.
...
PMID:p53 regulates katanin-p60 promoter in HCT 116 cells. 3171 1
Tumor suppressor protein
p53
protects cells against malignant transformation mostly through transcriptional activation. Lysine acetylation is required to mediate activation of
p53
. The protein displays eight lysine residues and their evolutionary conservation argues for an essential role. The aim of this study was to investigate the significance of individual acetylation sites in mediating
p53
functions. Differences in intracellular localization, protein expression levels, and transcriptional activity were investigated by overexpressing acetylation-deficient
p53
variants in the colon carcinoma-derived
p53
knock-out cell line HCT 116
p53
(-/-)
. We found that not all lysine residues are equally capable of promoting
p53
's functions. Individual amino acid mutations or combinations thereof led to altered
p53
expression levels, intracellular distribution, or transcriptional transactivation capacity, as compared to the wild-type protein. However, we observed that the choice of protein tag and expression vector could significantly alter obtained results on certain aspects of
p53
function.
...
PMID:Insights into the limitations of transient expression systems for the functional study of p53 acetylation site and oncogenic mutants. 3206 89
Tumor suppressor protein
p53
is the key factor in the regulation of cell proliferation. Its concentration is low in the cytoplasm of most cell types. However, in corneal epithelium cells, abnormally high
p53
content is detected. The aim of the present study was to characterize
p53
distribution in the corneal epithelium. For this purpose, immunohistochemistry, western blot analysis and electronic microscope examinations were performed. A low level of
p53
was identified in the lens, iris and retina; by contrast, a significantly high concentration of this protein was observed in the corneal epithelium. In opposite, MDM2 was identified in the lens, iris and retina while it is completely absent in the corneal epithelium. In addition, we found a significant amount of exosomes and other microvesicles containing
p53
in the corneal mucin layer. We thus hypothesize that a significantly high level of
p53
was caused by a combination of absents of MDM2 in parallel with
p53
microvesicles storage.
...
PMID:Features of p53 protein distribution in the corneal epithelium and corneal tear film. 3257 2
<< Previous
1
2
3
4